Crystal structure of quizartinib hydrate, C 29 H 32 N 6 O 4 S•(H 2 O) 1/3
Source abstract
Abstract
Abstract The crystal structure of quizartinib hydrate has been solved and refined using synchrotron X-ray powder diffraction data and optimized using density functional theory techniques. Quizartinib hydrate crystallizes in space group P-1 (#2) with a = 13.9133(9), b = 17.877(3), c = 19.8459(30) Å, α = 115.080(5), β = 93.768(5), γ = 100.831(5)°, V = 4,332.1(6) Å 3 , and Z = 6 at 298 K. In the complex crystal structure, the molecules are generally oriented parallel to the (110) plane. Two of the independent molecules are linked into dimers by N–H···O or N–H···N hydrogen bonds. Each molecule exhibits a unique pattern of C–H···O, C–H···N, or C–H···S hydrogen bonds. The powder pattern has been submitted to ICDD for inclusion in the Powder Diffraction File ™ (PDF ® ).
Source: crossref · Quality: baseline
Research context
OpenAlex topics: X-ray Diffraction in Crystallography · Crystallography and molecular interactions · Thermal and Kinetic Analysis
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Illinois Institute of Technology
North Central College
The International Centre for Diffraction Data (ICDD)
Funding
International Centre for Diffraction Data
References (32)
Show source-provided references
1. 10.1107/S205252061402290210.1107/S2052520614022902 ↗
2. 2023
3. 10.1107/S002188981300353110.1107/S0021889813003531 ↗
4. 10.1107/S160057672100291010.1107/S1600576721002910 ↗
5. 10.1021/acs.jctc.2c0095810.1021/acs.jctc.2c00958 ↗
6. 10.1017/S088571562400015010.1017/S0885715624000150 ↗
7. 10.1017/S088571561400051710.1017/S0885715614000517 ↗
8. 10.1107/S002188981101462210.1107/S0021889811014622 ↗
9. 2013
10. 10.1063/1.46788210.1063/1.467882 ↗
11. 10.1016/0927-0256(96)00008-010.1016/0927-0256(96)00008-0 ↗
12. 10.3406/bulmi.1907.282010.3406/bulmi.1907.2820 ↗
13. 10.1016/j.chphi.2022.10014710.1016/j.chphi.2022.100147 ↗
14. 10.1021/ci049780b10.1021/ci049780b ↗
15. 10.1093/nar/gkac95610.1093/nar/gkac956 ↗
16. 10.1107/S010876810000723010.1107/S0108768100007230 ↗
17. 2024b
18. 10.1107/S002188981301311310.1107/S0021889813013113 ↗
19. 2023
20. Bravais · 1866
21. 10.1002/anie.19951555110.1002/anie.199515551 ↗
22. 10.1107/S205252061600395410.1107/S2052520616003954 ↗
23. 10.1002/jcc.2315310.1002/jcc.23153 ↗
24. 2023
25. 10.1107/S160057752100249610.1107/S1600577521002496 ↗
26. 2024a
27. A New Law of Crystal Morphology Extending the Law of Bravais
28. 10.1007/BF0054909610.1007/BF00549096 ↗
29. Bhagwat, S. S. , Lai, W. , Parent, S. D. , Roe, M. J. , Schwartz, A. , and Smolenskaya, V. N. . 2014. “Solid Forms Comprising N-(5-tert-butyl-isoxazol-3-yl)-N’-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-B][1,3]benzothiazol-2-yl]phenyl]urea, Compositions Thereof, and Uses Therewith.” U.S. Patent 8883783B2.
30. 10.1021/ar00172a00510.1021/ar00172a005 ↗
31. 10.1017/S088571561400090610.1017/S0885715614000906 ↗
32. 10.1107/S160057671901409210.1107/S1600576719014092 ↗